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and within 12 weeks of treatmet of only 41.4%. Appropriate
psychosocial interventions were recommended in only 39.9%,
condition education in 33.4%, assessment for hyperglycemia
after initiation an atypical antipsychotic in 19.7% and weight
measurement in 15.5%) Psychiatric practices performed better
than primary care on most measures. A subset of patients were
double abstracted and demonstrated substantial simple agree-
ment ranging from 89.5% to 100% and kappa from 0.75 to
1.0. CONCLUSION: The need to improve quality of care for
individuals with bipolar disorder is signiﬁcant. These PM can
be implemented using chart audits and be a useful component
of quality improvement efforts.
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To introduce, deﬁne and differentiate between conceptual
models, endpoint models and conceptual frameworks, and to
discuss how they ﬁt together in the context of supporting product
claims in drug development. In addition, to explore the added
beneﬁt of including health economic concepts and endpoints
within the same framework. Using alcohol dependence (AD)
as an illustrative example, a conceptual model, hypothetical
endpoint model and conceptual framework (for a selected
AD-speciﬁc PRO measure) were developed, following the newly
issued guidance from the FDA relating to label claims. The
potential for combining each of these elements together with
related documents, such as the Target Product Proﬁle to support
a product claim, was assessed as was the feasibility of including
health economic claims within a similar framework. The devel-
opment of a holistic framework to support not only label claims,
but also value claims is presented. The framework develops the
recent guidance by the FDA for PROs and suggests that it may be
possible to include health economic outcomes within the general
framework. Doing so offers potential beneﬁts in relation to
applying the same rigorous treatment now required for PROs,
encourages genuine collaboration between different stakeholders
and provides a framework for communicating value concepts
outside the discipline of outcomes research. In particular, clear
speciﬁcation of health economic outcomes within an endpoint
model may assist with the design of prospective studies. Never-
theless, it is clear that value claims remain the responsibility of
reimbursement authorities rather than regulators. Each of the
models discussed are useful in supporting product claims in drug
development and, from a PRO perspective, endpoint models and
conceptual frameworks are essential. From a health economics
perspective, employing a similar framework encourages scientiﬁc
rigour, facilitates communication and could help design of appro-
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OBJECTIVE: Evaluate the prevalence and costs of
co-morbidities in employees with/without multiple sclerosis
(MS). METHODS: A United States employee health care claims
database from 2001–2007 was used to identify subjects with
MS (ICD-9 code = 340.XX) and a control cohort without MS.
The control group was matched 20:1 to the MS subjects on
demographics, job-information, geography, and Charlson Co-
morbidity Index. Based on ICD-9 codes, direct medical costs
associated with the Agency for Health care Research and Quality
17 Major and 261 Speciﬁc Diagnostic Categories (MDCs and
SCs) were identiﬁed. Index dates for the MS cohort were the
diagnosis or therapy initiation date, and for Controls the average
MS date. The 12-month post-index date utilization and costs
were analyzed. Prevalence comparisons were tested using
z-scores of log odds ratios and cohort cost comparisons using
t-tests (P < 0.05). RESULTS: A total of 765 employees with MS
and 15,300 matched controls were analyzed. The MS cohort had
signiﬁcantly higher prevalence of 15/17 MDCs and were sig-
niﬁcantly costlier in 7. The top more prevalent MDCs were:
Nervous System+Sense Organs, Musculo Connective Tissue,
and “Other Conditions” which had 53.4%, 18.2% and 17.1%
higher prevalence, respectively and were $1837, $256, and $241
more costly, respectively. However, it was surprising to see the
prevalence and higher cost of conditions like: Circulatory System
(31.1%–21.9%; $568–$235) Mental Disorders (20.7%–11.6%;
$147–$61) Digestive System (23.9%–16.2%; $369–$193); Skin
& Subcutaneous Tissue (25.4%–19.7%; $129–$69). Evaluating
these using the “speciﬁc categories”, signiﬁcantly higher preva-
lence and costs were reported among the MS cohort in: other
nervous system disorders, headache and migraine, epilepsy con-
vulsions, blindness and vision defects, dizziness/vertigo, other
mental conditions. CONCLUSION: Employees with MS have
more prevalent co-morbid conditions than subjects without MS.
From an insurer’s perspective, this increased burden for MS
sufferers is also associated with higher costs.
PND2
THE FABRY OUTCOME SURVEY (FOS):A DATABASE OF
PROSPECTIVE OBSERVATIONS ONTHE NATURAL HISTORY
AND MANAGEMENT OF A RARE DISEASE
Clarke J1, Beck M2, Giugliani R3, Sunder-Plassmann G4, Linhart A5,
Hernberg-Ståhl E6, Mehta A7
1Hospital for Sick Children,Toronto, Ontario, Canada, 2University of
Mainz, Mainz, Germany, 3Hospital de Clinicas/UFRGS, Porto Alegre,
RS, Brazil, 4Medical University Vienna,Vienna, Austria, 5Charles
University, Prague, Czech Republic, 6Shire Human Genetic Therapies,
Danderyd, Sweden, 7Royal Free Hospital, London, UK
OBJECTIVES: To analyse how the development of an industry-
sponsored, but physician directed, multinational database has
facilitated collection and interpretation of serial clinical and
laboratory observations on patients with Fabry disease—a rare
lysosomal storage disorder caused by deﬁciency of the enzyme
a-galactosidase A. METHODS: In 2001, physicians established
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the operating principles and protocols for collection, retention,
retrieval, and analysis of demographic information, signs and
symptoms—including laboratory ﬁndings—and the response to
enzyme replacement therapy with agalsidase alfa in patients with
a conﬁrmed diagnosis of Fabry disease. RESULTS: As of Decem-
ber 2007, 190 centres have enrolled 1453 patients from 19
countries worldwide (754 females, 699 males). Of these, 133 are
girls and 118 boys less than 18 years of age. Data from these
patients have added signiﬁcantly to our understanding of Fabry
disease, with 24 peer-reviewed publications describing the pre-
treatment characteristics of the disease and the response to
agalsidase alfa. Problems encountered include: 1) incomplete
ascertainment of patients with different manifestations of Fabry
disease; 2) some systematic lacunae in the data; and 3) uncer-
tainty about the quality of some data. Progress has been made in
overcoming these problems by: 1) convening regular meetings of
investigators to review protocols, data collection, and ﬁndings
from data analysis; 2) focusing on ‘core data’; 3) concentrating
on achieving comprehensive data collection from centres where
enrolment is especially high; and 4) employing clinical research
associates to increase data collection and ensure data quality.
CONCLUSIONS: FOS has contributed signiﬁcantly to the
understanding of the clinical features of Fabry disease in patients
of all ages. Problems with data collection and quality have been
addressed by a multi-faceted approach, including focusing on a
core panel of data to be collected, together with the use of clinical
research associates to check data completeness and quality.
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OBJECTIVE: Over the past decade, there has been a tremendous
increase in the prevalence of autism spectrum disorders (ASD) in
the United States. With increasing ASD prevalence, the health
care utilization and costs associated with these neurodevelop-
mental disabilities are also expected to increase. The purpose of
this study is to determine the trends in the prevalence of ASD and
ASD-related health care utilization and costs among recipients
enrolled in a state Medicaid program. METHODS: A retrospec-
tive descriptive analysis of a state Medicaid fee-for-service
administrative claims dataset was conducted. Medical services
claims with a primary, secondary, or tertiary diagnosis code of
ASD (ICD-9-CM 299.0/299.8) were extracted to determine the
prevalence of ASD. Claims for psychotropic medications
prescribed to recipients with ASD were then extracted using
de-identiﬁed unique recipient numbers obtained from the
medical services claims. Prevalence and health care utilization
numbers and rates were reported by demographic categories.
Costs were reported from the state Medicaid perspective.
RESULTS: Between 1996 and 2003, the number of recipients
identiﬁed with ASD increased from 246 to 1399, respectively. In
terms of age distribution, recipients in the age group 6–14 years
represented the highest proportion in all the study years, with the
proportion increasing from 38.6% in 1996 to 47.0% in 2003. A
majority of the recipients with ASD were males, who made
69.1% of the sample in 1996 and 74.6% in 2003. Whites con-
stituted a majority (>90%) with respect to ethnicity in all the
study years. The increase in the prevalence of ASD was accom-
panied by an increase in ASD-related health care utilization and
costs. CONCLUSION: Similar to national trends, the prevalence
of ASD increased considerably over the years in the state Med-
icaid program. In addition, the prevalence of ASD among Med-
icaid recipients varied by demographic characteristics. The study
provides useful data to better serve the needs of this growing
population.
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OBJECTIVES: Few studies have evaluated trends among inpa-
tients with cystic ﬁbrosis. The purpose of this paper is to explore
patient demographics, diagnosis, and procedures to gather a
general picture of cystic ﬁbrosis treatment. Exploration of the
cystic ﬁbrosis data set to ﬁnd trends among the variables, race,
gender, mortality, total charges, length of stay, age diagnosis, and
procedures provides insight into better methods to treat indi-
viduals with cystic ﬁbrosis. METHODS: The data used were
taken from the National Inpatient Sample (NIS). The cystic
ﬁbrosis data set was formed by isolating the NIS patients diag-
nosed with cystic ﬁbrosis, using a 10% sample from 2004. The
cystic ﬁbrosis data set contained 1582 observations. Descriptive
statistics were used to examine the data; chi-square tests and
logistic regressions were employed to analyze the data.
RESULTS: Statistics showed that patients with a longer length of
stay were more likely to die during hospitalization and to be
older. Most races had two high density ages; one around 20
years of age and the other around 60 years of age with the
exception of African Americans and Native Americans. The
three procedures: transfusion of packed cells (ICD-9 99.04),
continuous ventilation <96 consecutive hours (ICD-9 96.71),
and endotracheal tube insertion (ICD-9 96.04) and two diag-
noses pneumonia (ICD-9 486) and amyloidosis (ICD-9 277.3,
accumulate deposits of abnormal proteins) were found to be
directly related to mortality. The data also showed that none of
the patients with esophageal reﬂux (ICD-9 530.81) died during
hospitalization. CONCLUSIONS: From the results, older
patients, patients with long lengths of stay, or those diagnosed
with amyloidosis could be considered high-risk for hospital mor-
tality. However, these results are limited; no information about
outpatient factors, medications, or test results could be assessed.
Also, there were few patients who died during hospitalization on
which to base the analysis.
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OBJECTIVE: To assess the rate of substance abuse among
insomnia patients prescribed nonbenzodiazepine receptor
agonists (nBZRAs), benzodiazepines (BZDs), and melatonin
receptor agonists (MRAs). METHODS: This analysis used a
retrospective matched cohort design with data from Florida
Medicaid recipients 18 to 64 years old. Patients initiating
nBZRA, BZD, or MRA therapy between July 1, 2002 and March
31, 2006, without a history of substance abuse, were included in
this analysis. One MRA patient was matched to three nBZRA
and three BZD patients based n demographic and clinical
(history of insomnia, depression, anxiety) characteristics. Service
dates and days of medication supply variables from pharmacy
claims established periods of treatment exposure, while sub-
stance abuse related to sedatives and hypnotics was identiﬁed
using International Classiﬁcation of Diseases 9th edition Clinical
Modiﬁcation (ICD-9-CM) codes for the same time frame. Rates
of substance abuse (SA) were calculated as the number of
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